Regulation of Inflammation by IL-17A and IL-17F Modulates Non-Alcoholic Fatty Liver Disease Pathogenesis
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. While it is well-accepted that inflammation is central to NAFLD pathogenesis, the immune pathway(s) orchestrating disease progression are poorly defined. Notably, IL-17RA signaling, via IL-17A, plays an important role in obesity-driven NAFLD pathogenesis. However, the role of the IL-17F, another IL-17RA ligand, in NAFLD pathogenesis has not been examined. Further, the cell types expressing IL-17RA and producing IL-17RA ligands in the pathogenesis of NAFLD have not been defined. Here, IL-17RA-/-, IL-17A-/-, IL-17F-/- and wild-type (WT) mice were fed either standard chow diet or methionine and choline deficient diet (MCDD)--a diet known to induce steatosis and hepatic inflammation through beta-oxidation dysfunction--and hepatic inflammation and NAFLD progression were subsequently quantified. MCDD feeding augmented hepatic IL-17RA expression and significantly increased hepatic infiltration of macrophages and IL-17A and IL-17F producing CD4+ and CD8+ T cells in WT mice. In contrast, IL-17RA-/-, IL-17A-/-, and IL-17F-/- mice, despite increased steatosis, exhibited significant protection from hepatocellular damage compared to WT controls. Protection from hepatocellular damage correlated with decreased levels of hepatic T-cell and macrophage infiltration and decreased expression of inflammatory mediators associated with NAFLD. In sum, our results indicate that the IL-17 axis also plays a role in a MCDD-induced model of NAFLD pathogenesis. Further, we show for the first time that IL-17F, and not only IL-17A, plays an important role in NAFLD driven inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CD4 + T H 17 cells and CD8 + T cells have been shown to mediate NASH-associated liver fibrosis in both mice and humans (5-9).”
From NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis (2023) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689 · cited 1×
“This increased expression of IL-17RA correlated with a significant increase in hepatic CD11b+F4/ 80+ macrophage infiltration and a trend towards increased macrophage skewing to a proinflammatory phenotype [21] as quantified by macrophage Ly6C expression (Fig 1D and data not shown).”
BackgroundThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585 · cited 2×
“Notably, multiple clinical trials are currently employing the use of IL17A and IL-17RA antibodies for a variety of diseases [27].”
BackgroundInnate IL-17-producing cells: the sentinels of the immune system
Cua, D. J., & Tato, C. M. (2010) · Nature Reviews Immunology · doi:10.1038/nri2800 · Cited by 1,578
Structure and signalling in the IL-17 receptor family
Gaffen, S. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2586 · Cited by 1,475 · cited 3×
“Of interest, IL-17A and IL-17F signal through a heterodimeric receptor consisting of both IL-17RA and IL-17RC subunits [6].”
BackgroundNonalcoholic Fatty Liver Disease: Pathology and Pathogenesis
Tiniakos, D. G., Vos, M. B., & Brunt, E. M. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102132 · Cited by 870 · cited 4×
“NAFLD represents a spectrum of disorders ranging from steatosis (benign fat accumulation) to nonalcoholic steatohepatitis (NASH) and cirrhosis [1].”
BackgroundInfluentialKarlmark, K. R., Weiskirchen, R., Zimmermann, H. W., Gassler, N., Ginhoux, F., Weber, C., Merad, M., Luedde, T., Trautwein, C., & Tacke, F. (2009) · Hepatology · doi:10.1002/hep.22950 · Cited by 782 · cited 1×
“Importantly, proinflammatory macrophage infiltration has been associated with induction of hepatic inflammation and hepatocellular damage[22, 23].”
BackgroundMouse models in non‐alcoholic fatty liver disease and steatohepatitis research
Anstee, Q. M., & Goldin, R. D. (2006) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2006.00465.x · Cited by 714 · cited 1×
“Of note, the MCDD is known to robustly upregulate hepatic inflammation [32].”
BackgroundMeng, F., Wang, K., Aoyama, T., Grivennikov, S. I., Paik, Y., Scholten, D., Cong, M., Iwaisako, K., Liu, X., Zhang, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.049 · Cited by 711
Baeck, C., Wehr, A., Karlmark, K. R., Heymann, F., Vucur, M., Gassler, N., Huss, S., Klussmann, S., Eulberg, D., Luedde, T., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300304 · Cited by 609 · cited 1×
“Hepatic macrophage recruitment during NAFLD has been shown to be mediated by CCL2 production, a potent macrophage chemokine shown to be produced in response to CXCL10 expression [2, 33, 36].”
BackgroundZhang, J.-P., Yan, J., Xu, J., Pang, X.-H., Chen, M.-S., Li, L., Wu, C., Li, S.-P., & Zheng, L. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.033 · Cited by 535 · cited 1×
“Notably, IL-17A levels correlate with a variety of human hepatic disorders, including alcoholic liver disease [7], primary biliary cirrhosis [8], chronic hepatitis B and C [9, 10], liver transplant rejection [11] and hepatocellular carcinoma [12].”
Background
Research works printed but not linked: 1
- F Meng, 2012, Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice, Gastroenterology, 143, 765, 10.1053/j.gastro.2012.05.049 · DOI · Paper page
Cited by
Immune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Adaptive immunity: an emerging player in the progression of NAFLD
Sutti, S., & Albano, E. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0210-2 · Cited by 374
The Alterations in and the Role of the Th17/Treg Balance in Metabolic Diseases
Zhang, S., Gang, X., Yang, S., Cui, M., Sun, L., Li, Z., & Wang, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.678355 · Cited by 263
The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity
Van Herck, M. A., Weyler, J., Kwanten, W. J., Dirinck, E. L., De Winter, B. Y., Francque, S. M., & Vonghia, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00082 · Cited by 238
“Conversely, other authors report an increase in steatosis when IL-17 functionality is inhibited (65, 67).”
BackgroundResultInfluentialGiles, D. A., Moreno-Fernandez, M. E., Stankiewicz, T. E., Graspeuntner, S., Cappelletti, M., Wu, D., Mukherjee, R., Chan, C. C., Lawson, M. J., Klarquist, J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4346 · Cited by 242
Self-citationLiver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 218
Type I Interferon Responses Drive Intrahepatic T Cells to Promote Metabolic Syndrome
Ghazarian, M., Revelo, X. S., Nøhr, M. K., Luck, H., Zeng, K., Lei, H., Tsai, S., Schroer, S. A., Park, Y. J., Chng, M. H. Y., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aai7616 · Cited by 190
The eMERGE Network, Namjou, B., Lingren, T., Huang, Y., Parameswaran, S., Cobb, B. L., Stanaway, I. B., Connolly, J. J., Mentch, F. D., Benoit, B., et al. (2019) · BMC Medicine · doi:10.1186/s12916-019-1364-z · Cited by 179
Self-citationMoreno-Fernandez, M. E., Giles, D. A., Oates, J. R., Chan, C. C., Damen, M. S. M. A., Doll, J. R., Stankiewicz, T. E., Chen, X., Chetal, K., Karns, R., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.04.018 · Cited by 150
Self-citationBruzzì, S., Sutti, S., Giudici, G., Burlone, M. E., Ramavath, N. N., Toscani, A., Bozzola, C., Schneider, P., Morello, E., Parola, M., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.06.015 · Cited by 139
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
Self-citationImmunopathobiology and therapeutic targets related to cytokines in liver diseases
He, Y., Hwang, S., Ahmed, Y. A., Feng, D., Li, N., Ribeiro, M., Lafdil, F., Kisseleva, T., Szabo, G., & Gao, B. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00580-w · Cited by 137
CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease
Breuer, D. A., Pacheco, M. C., Washington, M. K., Montgomery, S. A., Hasty, A. H., & Kennedy, A. J. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00040.2019 · Cited by 113
CD4+ T cell activation and inflammation in NASH-related fibrosis
Zhou, Y., Zhang, H., Yao, Y., Zhang, X., Guan, Y., & Zheng, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967410 · Cited by 106
“It has been previously reported that IL-17 and IL-22 exhibit opposite effects in the development of NASH (86).”
BackgroundInfluentialMoreno-Fernandez, M. E., Giles, D. A., Stankiewicz, T. E., Sheridan, R., Karns, R., Cappelletti, M., Lampe, K., Mukherjee, R., Sina, C., Sallese, A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.93626 · Cited by 106
“Hepatic immune infiltration was quantified by flow cytometry of single cell suspensions following hepatic digestion as previously described (14, 16).”
BackgroundMethodInfluentialSelf-citationLiu, H., Zhan, X., Xu, G., Wang, Z., Li, R., Wang, Y., Qin, Q., Shi, W., Hou, X., Yang, R., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105384 · Cited by 106
IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases
Beringer, A., & Miossec, P. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.06.008 · Cited by 108
Paquissi, F. C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01195 · Cited by 93
“The Role of iL-17 Axis, and Associated Signaling Pathways, in Liver Fibrogenesis and Cirrhosis The subtype 17 of T helper lymphocyte cells is increased in almost all chronic and fibrosing liver diseases, including ALD, such as autoimmune hepatitis (AIH) (50, 110, 111), primary sclerosing cholangitis (PSC) (112, 113),…”
BackgroundInfluentialPaquissi, F. C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00490 · Cited by 94
“IL-17 is the most studied Th17-secreted cytokine in liver disease (15, 41, 42).”
BackgroundInfluentialGiles, D. A., Ramkhelawon, B., Donelan, E. M., Stankiewicz, T. E., Hutchison, S. B., Mukherjee, R., Cappelletti, M., Karns, R. A., Karp, C. L., Moore, K. J., et al. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.09.008 · Cited by 85
“qRT-PCR RNA was extracted from lysed tissue samples, and cDNA was transcribed according to previously described protocol [23,24].”
MethodSelf-citationMacrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack
Oates, J. R., McKell, M. C., Moreno-Fernandez, M. E., Damen, M. S. M. A., Deepe, G. S., Qualls, J. E., & Divanovic, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02893 · Cited by 73
“Immune Responses in NAFLD Dysregulated immune responsiveness is central to the development and progression of NAFLD (9, 10).”
BackgroundSelf-citationImmunomodulatory functions of FXR
Fiorucci, S., Zampella, A., Ricci, P., Distrutti, E., & Biagioli, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111650 · Cited by 70
Peiseler, M., & Tacke, F. (2021) · Cancers · doi:10.3390/cancers13040730 · Cited by 71
Hirsova, P., Bamidele, A. O., Wang, H., Povero, D., & Revelo, X. S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.760860 · Cited by 70
Interleukin-17 in Liver Disease Pathogenesis
Li, N., Yamamoto, G., Fuji, H., & Kisseleva, T. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730926 · Cited by 73
Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis
Chackelevicius, C. M., Gambaro, S. E., Tiribelli, C., & Rosso, N. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i41.9096 · Cited by 57
Hatasa, M., Yoshida, S., Takahashi, H., Tanaka, K., Kubotsu, Y., Ohsugi, Y., Katagiri, T., Iwata, T., & Katagiri, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073728 · Cited by 65
“In an analysis using mice, IL-17A-, IL-17F-, and IL-17RA-deficient mice showed liver steatosis in a fatty liver model due to a methionine choline-deficient diet, but the degree of liver dysfunction was significantly lower than that of wild-type mice [109].”
The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis
Méndez‐Sánchez, N., Valencia-Rodríguez, A., Coronel-Castillo, C. E., Vera-Barajas, A., Contreras-Carmona, J., Ponciano‐Rodríguez, G., & Zamora‐Valdés, D. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.184 · Cited by 57
Non‐alcoholic fatty liver disease and psoriasis – is there a shared proinflammatory network?
Heitmann, J., Frings, V. G., Geier, A., Goebeler, M., & Kerstan, A. (2021) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14425 · Cited by 62
Nascè, A., Gariani, K., Jornayvaz, F. R., & Szántó, I. (2022) · Antioxidants · doi:10.3390/antiox11061131 · Cited by 55
“In preclinical studies, diet-induced liver pathologies IL-17 promote the onset of NAFLD in mice [158,159].”
BackgroundStress kinases in the development of liver steatosis and hepatocellular carcinoma
Cicuéndez, B., Ruiz-Garrido, I., Mora, A., & Sabio, G. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101190 · Cited by 48
“Because Th17 cell-derived IL-17 participates in NAFLD progression and mice lacking an IL-17A or IL-17A receptor have less steatosis [161,162], research on the relative contribution of p38a in this process would contribute to the literature.”
BackgroundMarinović, S., Lenartić, M., Mladenić, K., Šestan, M., Kavazović, I., Benić, A., Krapić, M., Rindlisbacher, L., Cokarić Brdovčak, M., Sparano, C., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add1599 · Cited by 43
Al-Harbi, N. O., Nadeem, A., Al‐Harbi, M. M., Zoheir, K. M. A., Ansari, M. A., El‐Sherbeeny, A. M., Al‐Anazi, K. M., Alotaibi, M. R., & Ahmad, S. F. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.10.013 · Cited by 43
Van Herck, M. A., Vonghia, L., Kwanten, W. J., Julé, Y., Vanwolleghem, T., Ebo, D. G., Michielsen, P. P., De Man, J. G., Gama, L., De Winter, B. Y., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.04.010 · Cited by 43
Abdelnabi, M. N., Hassan, G. S., & Shoukry, N. H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1437046 · Cited by 46
Bosch, D. E., & Yeh, M. M. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.09.008 · Cited by 38
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
Petagine, L., Zariwala, M. G., & Patel, V. B. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i32.4831 · Cited by 44
Olveira, A., Augustín, S., Benlloch, S., Ampuero, J., Suárez‐Pérez, J. A., Armesto, S., Vilarrasa, E., Belinchón, I., Herranz, P., Crespo, J., et al. (2023) · Life · doi:10.3390/life13020419 · Cited by 44
Iboshi, Y., Nakamura, K., Fukaura, K., Iwasa, T., Ogino, H., Sumida, Y., Ihara, E., Akiho, H., Harada, N., & Nakamuta, M. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1221-1 · Cited by 39
“Alternatively, IL-17A and IL-17F together are regarded as potential therapeutic targets when blocking IL-17A alone is not effective [47, 48].”
Zhang, Z., Chen, X., & Cui, B. (2021) · Food & Function · doi:10.1039/d1fo00249j · Cited by 40
Vahid, F., Shivappa, N., Hekmatdoost, A., Hébert, J. R., Poustchi, H., Shamsipour, A., Eslamparast, T., Meibodi, M., & Rahmani, D. (2018) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831/a000571 · Cited by 34
Gau, S., Huang, K., Lee, C., Kuan, Y., Tsai, T., & Lee, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840106 · Cited by 40
“The IL-17 family (including IL17-A and IL17-E) has been reported to be involved in the development of NAFLD in an animal model (30).”
BackgroundShen, T., Chen, X., Li, Y., Tang, X., Jiang, X., Yu, C., Zheng, Y., Guo, H., & Ling, W. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.01.027 · Cited by 36
Biagioli, M., & Fiorucci, S. (2021) · Liver Research · doi:10.1016/j.livres.2021.08.003 · Cited by 37
“155,156 In mice feed a methionine-choline de fi cient diet (that is an imperfect model of NAFLD), the percentage of Th17 cells fl uctuates over time with two peaks: one in the initial stages of steatohepatitis and one in the last stages of the disease.”
Takamura, S., Teraki, Y., Katayama, E., Kawaguchi, T., Kawaguchi, M., Nakano, D., Tsutsumi, T., Nagoshi, S., Nakama, T., & Torimura, T. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0040 · Cited by 37
“Immune dysregulation mediated by the IL-17 pathway is the well-known pathogenesis of psoriasis.8 The IL-17 effectors cause keratinocyte hyperproliferation and inflammation.8 Whereas, overnutrition induces inflammation via T helper 17 cells and IL-17, resulting in neutrophil infiltration to adipose tissue, insulin resi…”
Inflammation and Immunity: From an Adipocyte's Perspective
Chan, C. C., Damen, M. S. M. A., Alarcon, P. C., Sánchez-Gurmaches, J., & Divanovic, S. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2019.0014 · Cited by 36
Self-citationFunctional heterogeneity of CD4+ T cells in liver inflammation
Muscate, F., Woestemeier, A., & Gagliani, N. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00881-w · Cited by 32
Nonalcoholic fatty liver disease and colorectal cancer: Correlation and missing links
Chakraborty, D., & Wang, J. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118507 · Cited by 36
Regulatory T-Cell Therapy in Liver Transplantation and Chronic Liver Disease
Hann, A., Oo, Y. H., & Perera, M. T. P. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719954 · Cited by 32
Oates, J. R., Sawada, K., Giles, D. A., Alarcon, P. C., Damen, M. S. M. A., Szabo, S., Stankiewicz, T. E., Moreno‐Fernandez, M. E., & Divanovic, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1095132 · Cited by 30
“Methionine-choline deficient diet WT C57BL/6 mice (8-week-old) were fed MCD diet (MCD; Research Diets #A02082002B; 16% Protein, 63% Carbohydrate and 21% Fat kcal/gram) and housed at either Ts or Tn for 4 or 10 weeks as previously described (10, 23).”
MethodSelf-citationÇebi, M., & Yilmaz, Y. N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1445634 · Cited by 30
Crucial role of T cells in NAFLD-related disease: A review and prospect
Mao, T., Yang, R. X., Luo, Y., & He, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1051076 · Cited by 33
“Increased number of CD8 T cells secreting interferon-gamma (IFN-g), IL-17A and IL-17F are observed in both hepatic microenvironment and peripheral blood in patients suffering from NASH and experimental mice model of NAFLD (50, 61, 70).”
BackgroundInfluentialMechanisms of liver fibrosis in metabolic syndrome
Mehal, W. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100015 · Cited by 28
Inflammatory processes involved in NASH-related hepatocellular carcinoma
Cannito, S., Dianzani, U., Parola, M., Albano, E., & Sutti, S. (2023) · Bioscience Reports · doi:10.1042/bsr20221271 · Cited by 31
Paquissi, F. C. (2016) · Journal of Biomarkers · doi:10.1155/2016/8160393 · Cited by 29
Świderska, M., Jaroszewicz, J., Stawicka, A., Parfieniuk‐Kowerda, A., Chabowski, A., & Flisiak, R. (2017) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2017.68466 · Cited by 28
“Concentration of IL-17A correlates with the inflammatory activity of different liver diseases including alcoholic liver disease [22] primary biliary cirrhosis, chronic hepatitis B and C, transplant rejection, and hepatocellular carcinoma [18].”
BackgroundFerrucci, V., Asadzadeh, F., Collina, F., Siciliano, R., Boccia, A. S., Marrone, L., Spano, D., Carotenuto, M., Chiarolla, C. M., Martino, D. D., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101938 · Cited by 27
Liu, J., Ding, M., Bai, J., Luo, R., Liu, R., Qu, J., & Li, X. (2023) · iMeta · doi:10.1002/imt2.76 · Cited by 25
“Notably, IL ‐ 17 axis including IL ‐ 17A, IL ‐ 17F, and IL ‐ 17A receptor (IL ‐ 17RA) actively participated in and even exacerbated hepatic infiltration of T cells and macrophages during the progression of MAFLD and steatohepatitis [70].”
BackgroundInterleukin 17A exacerbates ER-stress-mediated inflammation of macrophages following ICH
Yang, Z., Liu, Q., Shi, H. R., Jiang, X., Wang, S., Lu, Y., Zhang, J., Huang, X., & Yu, A. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.05.020 · Cited by 25
Retinoic Acid: A New Old Friend of IL-17A in the Immune Pathogeny of Liver Fibrosis
Kartasheva-Ebertz, D., Pol, S., & Lagaye, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691073 · Cited by 25
“The use of IL17A–deficient mice models has been shown to improve/resist to the development of steatohepatitis, a major risk factor of fibrosis (101, 102).”
MethodGan, Y., Zhao, X., He, J., Liu, X., Li, Y., Sun, X., & Li, Z. (2017) · Journal of Immunology Research · doi:10.1155/2017/4768408 · Cited by 24
“discovered that besides IL-17A, IL-17F also played an important role in the driven inflammation of nonalcoholic fatty liver disease [35].”
BackgroundThe Nr4a family regulates intrahepatic Treg proliferation and liver fibrosis in MASLD models
Aki, D., Hayakawa, T., Srirat, T., Shichino, S., Ito, M., Saitoh, S.-I., Mise-Omata, S., & Yoshimura, A. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175305 · Cited by 22
Mukherjee, R., Moreno‐Fernandez, M. E., Giles, D. A., Cappelletti, M., Stankiewicz, T. E., Chan, C. C., & Divanovic, S. (2018) · Hepatology Communications · doi:10.1002/hep4.1162 · Cited by 20
“Hepatic TG levels were quantified as described.((14,17,18)) Briefly, standards and samples were added to a 96-well, clear, flat-bottom plate (Costar) containing 200 lL of triglyceride reagent (Pointe Scientific).”
MethodSelf-citationKosmalski, M., Mokros, Ł., Kuna, P., Witusik, A., & Pietras, T. (2018) · Central European Journal of Immunology · doi:10.5114/ceji.2018.77395 · Cited by 21
Contribution of endotoxin to Th17 bias in patients with non-alcoholic steatohepatitis
Wang, X., Ji, D., Zhu, B., Jiang, S., Han, L., Wang, Y., Mai, H., Xu, S., Jiang, H., Wang, G., et al. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104009 · Cited by 18
Matsumoto, K., Kikuchi, K., Kuniyoshi, N., Tsunashima, H., Sekine, K., Mabuchi, M., Doi, S., Zen, Y., & Miyakawa, H. (2019) · Internal Medicine · doi:10.2169/internalmedicine.3204-19 · Cited by 16
“In addition, the involvement of Th17 cells and IL-17 has been reported in several animal models of NAFLD progressing to NASH (27-31).”
BackgroundPickich, M. B., Hargrove, M. W., Phillips, C. N., Healy, J. C., Moore, A. N., Roberts, M. D., & Martin, J. S. (2019) · BMC Research Notes · doi:10.1186/s13104-019-4540-5 · Cited by 17
Popov, J., Despot, T., Rodriguez, D. A., Khan, I. I., Mech, E., Khan, M. A., Bojadzija, M., & Pai, N. (2024) · Nutrients · doi:10.3390/nu16111668 · Cited by 16
“Th17 prevalence is also increased in murine models of MASH, particularly the CXCR3+ subset, which may play a role in the pathogenesis of disease [41–43].”
BackgroundHorakova, O., Sistilli, G., Kalendová, V., Bardová, K., Mitrovic, M., Čajka, T., Irodenko, I., Janovská, P., Lackner, K., Kopecký, J., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1205703 · Cited by 15
“expansion of the phylum Bacteroidetes) and augment intestinal permeability in HFD-fed B6/J mice (16, 36).”
BackgroundResultImmune Checkpoints and the Immunology of Liver Fibrosis
Tsomidis, I., Voumvouraki, A., & Kouroumalis, E. (2025) · Livers · doi:10.3390/livers5010005 · Cited by 16
Rationalizing heptadecaphobia: TH17 cells and associated cytokines in cancer and metastasis
Lücke, J., Shiri, A. M., Zhang, T., Kempski, J., Giannou, A. D., & Huber, S. (2021) · FEBS Journal · doi:10.1111/febs.15711 · Cited by 14
Jiang, X., Zhang, F., Ji, X., Dong, F., Yu, H., Xue, M., Qiu, Y., Yang, F., Hu, X., & Bao, Z. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155474 · Cited by 15
Li, D., Lü, C., & Yu, C. (2017) · PubMed Central · Cited by 13
Heredia, J. E., Sorenson, C., Flanagan, S., Núñez, V., Jones, C., Martzall, A., Leong, L., Paler-Martínez, A., Scherl, A., Brightbill, H. D., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274582 · Cited by 14
Wei, Z., & Wang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1375654 · Cited by 11
Takeshima, R., Kamata, M., Suzuki, S., Ito, M., Watanabe, A., Uchida, H., Chijiwa, C., Okada, Y., Azuma, S., Nagata, M., et al. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17277 · Cited by 12
Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis
Chung, K. W., Cho, Y. E., Kim, S.-J., & Hwang, S. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01379-1 · Cited by 11
Si, F., Feng, Y., & Han, M. (2017) · Genetics and Molecular Research · doi:10.4238/gmr16019076 · Cited by 11
“IL-17A and IL-17F are important pro-inflammatory cytokines that can be expressed in many cell types (Wedebye Schmidt et al., 2013; Giles et al., 2016; Orosz et al., 2016).”
BackgroundMatsuda, K. M., Kotani, H., Hisamoto, T., Kuzumi, A., Fukasawa, T., Yoshizaki‐Ogawa, A., Sato, S., & Yoshizaki, A. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156587 · Cited by 12
Relationship of IL-17A and IL-17F Genetic Variations to Cervical Cancer Risk: A Meta-Analysis
Yang, S., Li, Z., Li, X., Huang, X., Zhao, Q., Liu, D., & Wu, S. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0315 · Cited by 10
Supruniuk, E., Grubczak, K., Parfieniuk‐Kowerda, A., Flisiak, R., Moniuszko, M., Jaroszewicz, J., Chabowski, A., & Świderska, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1597204 · Cited by 11
Non-hematopoietic IL-4Rα expression contributes to fructose-driven obesity and metabolic sequelae
Damen, M. S. M. A., Stankiewicz, T. E., Park, S., Helsley, R. N., Chan, C. C., Moreno‐Fernandez, M. E., Doll, J., Szabo, S., Herbert, D. R., Softic, S., et al. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00902-6 · Cited by 12
“25 μg/mouse) challenge, and serum cytokine levels were determined 4 h later using in vivo cytokine capture assay (IVCCA) as previously described [24, 25, 27, 31].”
MethodSelf-citationThe Role of CD4+T Cells in Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma
Miao, Y., Li, Z., Feng, J., Lei, X., Shan, J., Qian, C., & Li, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136895 · Cited by 12
The Roles of T Cells in the Development of Metabolic Dysfunction‐Associated Steatohepatitis
Ge, Z., Wu, Q., Lv, C., & He, Q. (2025) · Immunology · doi:10.1111/imm.13943 · Cited by 8
Lebwohl, M., Merola, J. F., Strober, B. E., Armstrong, A. W., Yoshizaki, A., Gisondi, P., Szilagyi, B., Peterson, L., Cuyper, D. D., Cross, N., et al. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.03.041 · Cited by 7
IL-17F depletion accelerates chitosan conduit guided peripheral nerve regeneration
Chen, F., Liu, W., Zhang, Q., Wu, P., Xiao, A., Zhao, Y., Zhou, Y. F., Wang, Q., Chen, Y., & Tong, Z. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01227-1 · Cited by 7
“Animals 8 ~ 10-week-old male Il17f −/− (KO) [11, 41] and wildtype (WT) C57BL/6 mice were used in this study.”
MethodBosch, D. E., Zen, Y., Boukhar, S., Liu, Y.-J., Cheng, L., & Yeh, M. M. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03183-6 · Cited by 8
Immunology and treatments of fatty liver disease
Tang, S., Wu, S., Zhang, W., Ma, L., Zuo, L., & Wang, H. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03920-1 · Cited by 6
“Th17 cells mainly secrete IL-17 , IL-22 IL-22, However, other studies have reported contrasting findings, where functional blockade of IL-17 resulted in increased hepatic steatosis (Giles et al. 2016; Harley et al. 2014).”
Coste, S. C., Orasan, O. H., Cozma, A., Negrean, V., Alexescu, T., Perné, M.-G., Ciulei, G., Hangan, A. C., Lucaciu, R. L., Iancu, M., et al. (2024) · Life · doi:10.3390/life14101327 · Cited by 6
“In NASH, these cytokines induce inflammation and fibrosis by activating hepatic stellate cells and worsening insulin resistance, contributing to metabolic dysfunction [10].”
BackgroundRole of CD4+ T-cells in the pathology of non-alcoholic fatty liver disease and related diseases
Seike, T., Mizukoshi, E., & Kaneko, S. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2021.46 · Cited by 6
Su, S.-B., Chen, W., Huang, F., & Zhang, J. (2018) · European Journal of Inflammation · doi:10.1177/2058739218802678 · Cited by 6
Liu, M., Ma, Y., Cheang, W. S., Su, Z., & Xu, S. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.011 · Cited by 11
Wu, K., Zhu, J., Ma, Y., Zhou, Y., Lin, Q., Tu, T., & Liu, Q. (2023) · Scientific Reports · doi:10.1038/s41598-023-44884-z · Cited by 6
“Several studies have shown that the activated IL-17 axis contributes to the development and progression of NAFLD to steatohepatitis 38,48 .”
BackgroundHeitmann, J., Frings, V. G., Geier, A., Goebeler, M., & Kerstan, A. (2021) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14425_g · Cited by 5
Identification of Key Biomarkers and Immune Infiltration in Liver Tissue after Bariatric Surgery
Zhang, X., Li, J., Liu, T., Zhao, M., Liang, B., Chen, H., & Zhang, Z. (2022) · Disease Markers · doi:10.1155/2022/4369329 · Cited by 6
“The cytokine network produced by TH1, TH17, and CD8+ lymphocytes provides a potent stimulus for the activation of M1 macrophages, thus creating further occurrence of liver inflammation [46, 95, 96].”
BackgroundRetractedChen, Y., Jia, B., Tong, X., Yin, S., Ni, W., Zhao, Q., Shi, J., & Li, J. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000864 · Cited by 6
“…been shown to protect against MASH development, inherently reducing hepatic lipid accumulation and attenuating fibrosis in some models, [25,29] while other studies paradoxically report that IL-17 blockade may exacerbate steatosis, [30,31] highlighting the context-dependent nature of this pathway.”
Effects of interleukin 17A (IL-17A) neutralization on murine hepatitis virus (MHV-A59) infection
Aparicio, J. L., Ottobre, M., Vega, M. D., Coutelier, J., Snick, J. V., & Retegui, L. A. (2017) · European Cytokine Network · doi:10.1684/ecn.2017.0399 · Cited by 4
“IL-17RA is expressed ubiquitously, ncluding expression by resident liver cells [2].”
BackgroundImmune cells in liver regeneration: Current evidence and potential clinical targets
Moore, H. F., Usmani, S., Froghi, S., Rashidi, H., Quaglia, A., Fuller, B. J., & Davidson, B. R. (2025) · International Reviews of Immunology · doi:10.1080/08830185.2025.2531820 · Cited by 5
“The IL-17 axis can regulate T-cell infiltration into the liver [181] and IL-17 production by ILC3 lacking the natural cytotoxicity receptor (NCR - ILC3) induces CD8 T-cell apoptosis in carcinogenic liver microenvironments [25].”
A shift in PKM2 oligomeric state instructs adipocyte inflammatory potential
Damen, M. S. M. A., Alarcon, P. C., Chan, C. C., Stankiewicz, T. E., Chung, H., Sawada, K., Ulanowicz, C. J., Eom, J., Oates, J. R., Wayland, J. L., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.185914 · Cited by 3
“Hepatic triglycerides were quantified using the Triglyceride Reagent and Tri-glyceride Standards (Pointe Scientific) as described previously (75–77) from WT and Pkm2 fl/fl Adipoq Cre mice.”
Self-citation
Metadata
- Authors
- Giles, D. A., Moreno-Fernandez, M. E., Stankiewicz, T. E., Cappelletti, M., Huppert, S. S., Iwakura, Y., Dong, C., Shanmukhappa, S. K., & Divanovic, S.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- Research Institute for Biomedical Sciences, Tokyo University of Science (JP)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Divanovic, Senad
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-02-19
- Volume
- 11
- Issue
- 2
- Pages
- e0149783
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4760740
- OpenAlex
- W2283265313
- Cited by
- 116
- References
- 49
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 13 · 2023: 12 · 2022: 12 · 2021: 25 · 2020: 7 · 2019: 8 · 2018: 9 · 2017: 11 · 2016: 7
- FWCI
- 10.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Cincinnati Children's Hospital Medical Center (P30DK078392, R01DK099222)
- National Institutes of Health (DK078392)
- Japan Society for the Promotion of Science (15H05787, 24220011)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK099222, P30DK078392)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, IL-17A, IL-17F, liver inflammation, methionine-choline-deficient diet, steatosis, hepatocyte injury, macrophage infiltration, T cell infiltration
- MeSH terms
- Animals, Choline, Diet, Disease Models, Animal, Hepatitis, Macrophages, Male, Methionine, Mice, Inbred C57BL, T-Lymphocytes, Signal Transduction, Interleukin-17, Mice, Receptors, Interleukin-17, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.